You just read:

FDA Accepts Rigel's New Drug Application for TAVALISSE™ (fostamatinib disodium) for the Treatment of Chronic ITP

News provided by

Rigel Pharmaceuticals, Inc.

19 Jun, 2017, 07:30 ET